Hershkovich J, Broides A, Kirjner L, Smith H, Gorodischer R
Paediatric Allergy Clinic, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Clin Exp Allergy. 2009 May;39(5):726-30. doi: 10.1111/j.1365-2222.2008.03180.x. Epub 2009 Jan 22.
In patients who were clinically diagnosed as having beta lactam allergy and had negative skin tests, the rates of reported resensitization to beta lactams after subsequent exposures, vary significantly. Some allergists advocate skin testing before every exposure to beta lactams.
We sought to determine the true rate of beta lactam allergy and of resensitization in children with a positive history for suspected beta lactam allergy.
The study was conducted from July 1998 to May 2004, with follow-up during 2007. Beta lactam allergy tests with the major determinant and freshly prepared minor determinant mixtures were offered to history positive children. Negative skin tests were followed by oral challenge. The tests were performed again 1-5 months later in order to address the possibility of resensitization.
Tests were performed on 166 children: 150 for penicillins alone, 14 for penicillin in combination with cephalosporins, and an additional 2 patients solely for cephalosporins. Only 10 children (6%) were positive in the initial evaluation, four by skin test and six by oral challenge. A second set of tests was performed in 98 children with a negative initial evaluation; only two children (2%) were resensitized. On a follow-up survey of 71 of the 96 patients, 59 (83%) had received beta lactams; only one had developed a minor rash after subsequent exposure to amoxicillin.
Most children with suspected beta lactam allergy were not allergic to beta lactams. Resensitization to beta lactam antibiotics in children in this study was infrequent. In children with a clinical diagnosis of beta lactam allergy and negative skin tests, repeated skin testing before every exposure is usually unnecessary.
在临床诊断为β-内酰胺类过敏且皮肤试验阴性的患者中,后续再次接触β-内酰胺类药物后报告的再致敏率差异很大。一些过敏症专科医生主张在每次接触β-内酰胺类药物之前进行皮肤试验。
我们试图确定有疑似β-内酰胺类过敏阳性病史儿童中β-内酰胺类过敏和再致敏的真实发生率。
该研究于1998年7月至2004年5月进行,并在2007年进行随访。对有病史阳性的儿童进行主要决定簇和新配制的次要决定簇混合物的β-内酰胺类过敏试验。皮肤试验阴性后进行口服激发试验。1至5个月后再次进行试验,以探讨再致敏的可能性。
对166名儿童进行了试验:仅对青霉素进行试验的有150名,对青霉素联合头孢菌素进行试验的有14名,另外仅对头孢菌素进行试验的有2名患者。在初始评估中只有10名儿童(6%)呈阳性,4名通过皮肤试验阳性,6名通过口服激发试验阳性。对98名初始评估为阴性的儿童进行了第二轮试验;只有2名儿童(2%)发生再致敏。在对96名患者中的71名进行随访调查时,59名(83%)接受了β-内酰胺类药物治疗;只有1名在随后接触阿莫西林后出现轻微皮疹。
大多数有疑似β-内酰胺类过敏的儿童对β-内酰胺类药物不过敏。本研究中儿童对β-内酰胺类抗生素的再致敏并不常见。对于临床诊断为β-内酰胺类过敏且皮肤试验阴性的儿童,通常无需在每次接触前重复进行皮肤试验。